This study highlights the promising inhibitory potential of [125I]anastrozole and [125I]epirubicin, particularly [125I]epirubicin, against AKT1, suggesting that these compounds could serve as valuable leads in the development of new therapeutic agents for breast cancer. This evidence concerns the gene AKT1 and breast carcinoma.